Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imsidolimab in palmoplantar pustulosis
NCT03633396Phase 2Completed
- Sponsor
- Vanda Pharmaceuticals Inc.
- Start
- May 2019
- Primary completion
- Apr 2021
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 4
01
Overview
A Phase 2 trial of imsidolimab in palmoplantar pustulosis (PPP), sponsored by Vanda Pharmaceuticals Inc.. Started May 2019; status: completed.
02
Drugs
imsidolimab
03
Conditions
palmoplantar pustulosis (PPP)
Beyond the preview
Go deeper on NCT03633396.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03633396.